



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: June 5, 2009

To: NCCTG Primary Clinical Research Associates

From: Janis Wobschall
Protocol Development Coordinator

Re: N0177, A Phase I/II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

The Evaluation Treatment Forms for Cycle 1 and After Cycle 2 have been revised as follows:

Form Title	Brief Description of Edit
Evaluation/Treatment Form Cycle 1 (Weeks 1 through 7)	<ul style="list-style-type: none">• 181-Pain - eye Added to OSI-774 column under "Primary Reason for Dose Adjustment..."
Evaluation/Treatment Form After Cycle 1 (completion of RT)	<ul style="list-style-type: none">• 181-Pain - eye Added to OSI-774 column under "Primary Reason for Dose Adjustment..."

If you have any questions concerning this communication, please contact me at 507/284-8670.

Thank you.

JW/dg
enclosures